Designation of Amikacin Sulfate as an Orphan Drug - Novotech (Australia)

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves to regulate therapeutic goods including medicines, medical devices, and blood products. This Act was designed to address issues related to the safety, quality, and efficacy of therapeutic goods available in Australia, ensuring they meet necessary standards before entering the market. One specific issue it addresses is the need for incentivising the development and availability of treatments for rare or orphan diseases, which typically affect a small number of people and may not be economically viable for pharmaceutical companies to develop without support. In this context, the Act includes provisions for designating certain drugs as orphan drugs, thereby facilitating their development and availability. On 26 February 2015, Dr Anthony Gill, acting as the Delegate of the Secretary, designated amikacin sulfate as an orphan drug for the treatment of Nontuberculous Mycobacterial lung infection in adults who are refractory to current treatment, under the authority granted by the Therapeutic Goods Regulations 1990. This designation aims to encourage the research, development, and supply of orphan drugs for rare conditions, thereby addressing a significant gap in the therapeutic landscape for such diseases.

Scope and Application

The Therapeutic Goods Act 1989, as amended and implemented by the Therapeutic Goods Administration (TGA), designates amikacin sulfate as an orphan drug specifically for the treatment of Nontuberculous Mycobacterial (NTM) lung infection in adult patients who are refractory to current treatment. This designation is intended to encourage the development and availability of therapeutic goods for rare diseases or conditions that lack adequate treatment options. The drug, amikacin sulfate in the form of a suspension for inhalation, is sponsored by Novotech (Australia) Pty Limited. This Act applies to the sponsor and any other entities involved in the development, manufacture, or supply of amikacin sulfate for the designated use. The geographic scope of the Act is national, applying across the Commonwealth of Australia, and it aims to ensure that orphan drugs meet the necessary standards for safety, quality, and efficacy. The designation under the Therapeutic Goods Regulations 1990 does not include exclusions or exemptions specific to this instance, but the broader Act and Regulations provide mechanisms for further regulation through subordinate instruments, potentially extending or restricting application as needed to address specific therapeutic needs or regulatory developments.

Key Provisions

The key provisions of this legislation concern the designation of amikacin sulfate as an orphan drug under the Therapeutic Goods Act 1989. Specifically, section 16J of the Therapeutic Goods Regulations 1990 allows for the designation of certain drugs as orphan drugs if they meet specific criteria. In this instance, amikacin sulfate has been designated as an orphan drug (section 16J(2)) for the treatment of Nontuberculous Mycobacterial (NTM) lung infection in adults who do not respond to existing treatments. This designation is for the specific dose form of amikacin sulfate, which is a suspension for inhalation. This means that the drug has been identified for its potential to address a serious condition that currently lacks adequate treatment options. The obligations imposed by this legislation primarily fall on the sponsor of the drug, in this case, Novotech (Australia) Pty Limited. The sponsor is responsible for ensuring that the drug meets the requirements set forth in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. This includes complying with all relevant standards, guidelines, and procedures for the development, manufacture, and distribution of therapeutic goods. The sponsor must also ensure that the drug is safe, of high quality, and effective for its intended use. The legislation also outlines potential consequences for non-compliance. While the specific section of the Act detailing offences and penalties is not included in the excerpt, it is common for such regulatory frameworks to include provisions for both civil and criminal penalties. Civil penalties may include fines, while criminal penalties could involve imprisonment, depending on the severity and intent of the breach. The maximum penalties would be determined by the specific regulations and could vary widely. It is essential for the sponsor to adhere strictly to the regulations to avoid these consequences.